22276-95-5

Usage

Uses

Used in Organic Synthesis:
5-Bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine is used as a key intermediate for the synthesis of various complex organic molecules. Its unique structural features allow for further functionalization and modification, making it a valuable component in the development of novel chemical entities.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine is used as a building block for the development of new drugs. Its chemical properties enable it to be incorporated into drug candidates targeting a wide range of therapeutic areas, including oncology, neurology, and cardiovascular diseases.
Used in Agrochemicals:
5-Bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine is also utilized as a starting material in the agrochemical industry for the synthesis of various pesticides and insecticides. Its structural diversity allows for the development of new compounds with improved efficacy and selectivity against target pests.
Used in Dyestuff Industry:
In the dyestuff industry, 5-Bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine is employed as a crucial intermediate for the production of various dyes and pigments. Its unique chromophoric properties contribute to the development of new colorants with enhanced color strength, stability, and application performance.

InChI:InChI=1/C6H3BrClN3/c7-3-1-9-6-4(3)5(8)10-2-11-6/h1-2H,(H,9,10,11)

Upstream product

• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 144927-56-0 4-chloro-5-(methylthio)-7H-pyrrolo[2,3-d]pyrimidine 
• 144927-57-1 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylic acid ethyl ester 
• 582313-57-3 4-chloro-7-fluoro-7-deazapurine 
• 952429-11-7 (2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diyl dibenzoate 
• 952429-12-8 5-bromo-4-chloro-7-(2,3,5-tri-O-benzoyl-β-L-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 21193-61-3 4-amino-5-bromo-7-(β-L-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 
• 21193-80-6 5-Bromotubercidin 
• 252723-17-4 7-Benzenesulfonyl-5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 1256339-53-3 ((2R,3R,4R,5S)-3-(benzoyloxy)-5-(5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-4-fluoro-4-methyltetrahydrofuran-2-yl)methyl benzoate 
• 1351533-44-2 tert-butyl (4-(5-(3-(hydroxymethyl)phenyl)-7-((2-(trimethylsilyl)-ethoxy)-methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholin-2-yl)methyl-carbamate 
• 1034769-08-8 3-(4-(2-(aminomethyl)morpholino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile 
• 1034769-06-6 (3-(4-(2-(aminomethyl)morpholino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl)methanol 
• 1351533-43-1 tert-butyl (4-(5-(3-cyanophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholin-2-yl)methylcarbamate 
• 1351533-45-3 tert‐butyl ((4‐(5‐(3‐cyanophenyl)‐7H‐pyrrolo[2,3‐d]pyrimidin‐4‐yl)morpholin‐2‐yl)methyl)carbamate 

Relevant academic research and scientific papers

COMPOUND HAVING TRKA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR ALLEVIATING PAIN, CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a compound having TrkA inhibitory activity and a pharmaceutical composition for preventing or treating pain containing the same as an active ingredient. The compound provided in one aspect of the present invention has excellent TrkA inhibitory activity and exhibits excellent pain inhibitory effects in an animal model of pain after a surgery, and thus can be effectively used as an analgesic.

The method of its use and [tetorahidoropiraniruamino[tetorahidoropiraniruamino][piroropirimijinon[piroropirimijinon] - (by machine translation)

[Problem] an immune disorder, cancer, cardiovascular diseases, viral infection, inflammation, metabolic/endocrine dysfunction, neurological disorder having a possibility, potent small molecule inhibitors of BTK. [Solution] adjusting the activity of BTK, f

TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USE THEREOF

The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition compris

Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity

Continuous optimization of benzylic substituents on 1-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-1-yl)-2-phenylethan-1-one structure as Akt inhibitors was described in this paper. Particularly, compounds 8 and 14g exhibited high enzymatic potency against all Akt isoforms and antiproliferative effects in mantle cell lymphoma cell lines, as well as favorable cytotoxicities in patient primary cancer cells. Low micromolar doses of both 8 and 14g dose-dependently induced cell apoptosis and G2/M cell cycle arrest, also suppressed the phosphorylation level of Akt downstream targets GSK3β and S6.

PYRROLOPYRIMIDINE ITK INHIBITORS

Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.

Synthesis and anti-HBV activity of carbocyclic nucleoside hybrids with salient features of entecavir and aristeromycin

Modified carbocyclic nucleosides (4a-g) constituting 7-deazapurine, 4′-methyl, exocyclic double bond and 2′,3′-hydroxy were synthesized. NOE and X-ray studies of4cconfirmed the α-configuration of 4′-methyl. The anti-HBV assay demonstrated4e(IC50/sub

Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis

A series of 7H-pyrrolo[2,3-d]pyrimidine derivatives were designed and synthesized as reversible BTK inhibitors, and evaluated their kinase selectivity, anti-proliferation against the B-cell lymphoma cell lines (Ramos, Jeko-1) and cell line BTK enhanced (Daudi) in vitro. Among them, compound 28a exhibited the most excellent potency (IC50 = 3.0 nM against BTK enzyme, 8.52 μM, 11.10 μM and 7.04 μM against Ramos, Jeko-1, Daudi cells, respectively), good kinase selectivity and inhibited BTK Y223 auto-phosphorylation and PLCγ2 Tyr1217 phosphorylation. Importantly, 28a showed efficacy anti-arthritic effect on collagen-induced arthritis (CIA) model in vivo. 28a 60 mg/kg dose level once a day group displayed markedly reduced joint damage and cellular infiltration without any bone and cartilage morphology change.

Piperidine-containing pyrrolopyrimidine compound and preparation method and application thereof

The invention discloses a piperidine-containing pyrrolopyrimidine compound and a preparation method and application thereof. The piperidine-containing pyrrolopyrimidine compound adopts the structure shown in the general formula (I) or (II). The invention

SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASE 5 (PRMT5)

The disclosure is directed to compounds of Formula I, Formula II, and Formula III [Formulas should be inserted here]. Methods of their use and preparation are also described.

Substituted p-chlorophenyl acetylpiperazine-containing compound as well as preparation method and application thereof

The application provides a substituted p-chlorophenyl acetylpiperazine-containing compound as well as a preparation method and application of the substituted p-chlorophenyl acetylpiperazine-containingcompound. The compound has the structure shown in the formula (I), and has better Akt1 inhibitory activity or growth inhibitory activity to MCL cell lines.